Drug monitoring and viral response to lopinavir/ritonavir or saquinavir/ritonavir containing regimens in individuals infected with the human immunodeficiency virus type 1.
The aim of this study was to correlate results of therapeutic drug monitoring, genotypic resistance and viral response to lopinavir/ritonavir (LPV/r) or saquinavir/ritonavir (SQV/r) containing antiretroviral regimens. The retrospective short-term study included 20 patients with LPV/r and 20 patients with SQV/r containing highly active antiretroviral therapy (HAART). At baseline 7 LPV/r patients and 10 SQV/r patients had CD4+T cell counts above 410 cells/microl. After 6 months CD4+T cells had doubled in 5 LPV/r and 2 SQV/r patients. In LPV/r patients the mean serum concentration of lopinavir (LPV) was 2.6 ppm and 67% of all LPV/r samples had 50 or fewer viral copies/ml. In SQV/r patients the mean serum concentration of saquinavir (SQV) was 2.1 ppm. 79% of all SQV/r samples had 50 or fewer viruses/ml. Pharmacoenhanced regimens efficiently suppress human immunodeficiency virus type 1 (HIV-1) and the risk of developing resistance mutations is therefore reduced. The implementation of drug monitoring is an additional tool to determine optimal treatment conditions.
Falkensammer
B
B
Department of Hygiene, Microbiology and Social Medicine and Ludwig-Bolzmann-Institute for AIDS Research, Innsbruck Medical University, Austria. Barbabra.Falkensammer@uibk.ac.at
Fasser
W
W
Scherer
K
K
Zemann
A
A
Parson
W
W
Ulmer
H
H
Dierich
M P
MP
Stoiber
H
H
D000328:Adult; D019380:Anti-HIV Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D015704:CD4 Antigens / Q000235:genetics; D016903:Drug Monitoring; D005260:Female; D005838:Genotype; D015483:HIV Antibodies / Q000032:analysis / Q000096:biosynthesis; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D016333:HIV Protease / Q000235:genetics; D015497:HIV-1 / Q000201:enzymology / Q000235:genetics; D006801:Humans; D061466:Lopinavir; D008297:Male; D008875:Middle Aged; D009154:Mutation; D019798:Neopterin / Q000097:blood; D011744:Pyrimidinones / Q000493:pharmacokinetics / Q000627:therapeutic use*; D012189:Retrospective Studies; D019438:Ritonavir / Q000493:pharmacokinetics / Q000627:therapeutic use*; D019258:Saquinavir / Q000493:pharmacokinetics / Q000627:therapeutic use*
D019380:Anti-HIV Agents; D015704:CD4 Antigens; D015483:HIV Antibodies; D011744:Pyrimidinones; D061466:Lopinavir; D019798:Neopterin; D016333:HIV Protease; D019258:Saquinavir; D019438:Ritonavir